USE OF SSRI AND SNRI DURING PREGNANCY AND THE RISK OF PRETERM BIRTH, LOW BIRTH WEIGHT, AND NEONATAL ADAPTATION DISORDERS: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.31435/ijitss.1(49).2026.5046Keywords:
SSRI, SNRI, Pregnancy, Preterm Birth, Low Birth Weight, Neonatal Adaptation SyndromeAbstract
Background: Depression affects 10–15% of pregnant women and poses significant clinical management challenges. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are first-line treatments, yet their safety profile in pregnancy remains an active area of research and clinical concern.
Objective: This systematic review synthesizes evidence from 2015–2025 on associations between SSRI/SNRI use during pregnancy and risks of preterm birth (PTB), low birth weight (LBW), and poor neonatal adaptation syndrome (PNAS), with attention to confounding by maternal depression.
Methods: A comprehensive search of PubMed, Cochrane Library, and related databases identified meta-analyses, systematic reviews, and large cohort studies published 2015–2025. Outcomes examined included PTB (<37 weeks), LBW (<2500g), and PNAS.
Results: SSRI exposure during pregnancy is associated with modest increases in PTB risk (adjusted OR approximately 1.2–1.5) and LBW (relative risk ~1.4), with strongest effects for late-pregnancy exposure. PNAS occurs in 20–30% of infants exposed in the third trimester (adjusted OR ~2.1), typically mild and self-limited. SNRI data are more limited but show similar patterns. Confounding by indication - the underlying maternal depression - contributes substantially to observed associations.
Conclusions: Both untreated maternal depression and antidepressant exposure carry risks. Clinical decision-making should involve individualized risk–benefit assessment, shared decision-making, and recognition that sertraline and escitalopram demonstrate favorable safety profiles. Absolute risk increases are modest and must be weighed against consequences of untreated illness.
References
American College of Obstetricians and Gynecologists. (2023). Treatment and management of mental health conditions during pregnancy and postpartum (Clinical Practice Guideline No. 4). Obstetrics & Gynecology, 141(6), e85–e122. https://doi.org/10.1097/AOG.0000000000005202
American College of Obstetricians and Gynecologists. (2025, July). Statement on the benefit of access to SSRIs during pregnancy. https://www.acog.org/news/news-releases/2025/07/statement-on-benefit-of-access-to-ssris-during-pregnancy
Chambers, C. D., Hernandez-Diaz, S., Van Marter, L. J., Werler, M. M., Louik, C., Jones, K. L., & Mitchell, A. A. (2006). Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New England Journal of Medicine, 354(6), 579–587. https://doi.org/10.1056/NEJMoa052744
Grigoriadis, S., VonderPorten, E. H., Mamisashvili, L., Roerecke, M., Rehm, J., Dennis, C.-L., Koren, G., Steiner, M., Mousmanis, P., Cheung, A., & Ross, L. E. (2014). Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: Systematic review and meta-analysis. BMJ, 348, f6932. https://doi.org/10.1136/bmj.f6932
Grigoriadis, S., VonderPorten, E. H., Mamisashvili, L., Tomlinson, G., Dennis, C.-L., Koren, G., Steiner, M., Mousmanis, P., Cheung, A., Radford, K., Martinovic, J., & Ross, L. E. (2013). The impact of maternal depression during pregnancy on perinatal outcomes: A systematic review and meta-analysis. Journal of Clinical Psychiatry, 74(4), e321–e341. https://doi.org/10.4088/JCP.12r07968
Huang, H., Coleman, S., Bridge, J. A., Yonkers, K., & Katon, W. (2014). A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. General Hospital Psychiatry, 36(1), 13–18. https://doi.org/10.1016/j.genhosppsych.2013.08.002
Huang, L., Wang, Y., Zhang, L., Zheng, Z., Zhu, T., Qu, Y., & Mu, D. (2020). Antidepressant use in depressed women during pregnancy and the risk of preterm birth: A systematic review and meta-analysis of 23 cohort studies. Frontiers in Pharmacology, 11, 659. https://doi.org/10.3389/fphar.2020.00659
Huybrechts, K. F., Bateman, B. T., Palmsten, K., Desai, R. J., Patorno, E., Gopalakrishnan, C., Levin, R., Mogun, H., & Hernandez-Diaz, S. (2015). Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA, 313(21), 2142–2151. https://doi.org/10.1001/jama.2015.5605
Jarde, A., Morais, M., Kingston, D., Giallo, R., MacQueen, G. M., Giglia, L., Beyene, J., Wang, Y., & McDonald, S. D. (2016). Neonatal outcomes in women with untreated antenatal depression compared with women without depression: A systematic review and meta-analysis. JAMA Psychiatry, 73(8), 826–837. https://doi.org/10.1001/jamapsychiatry.2016.0934
Jarde, A., Morais, M., Kingston, D., Giallo, R., MacQueen, G. M., Giglia, L., Beyene, J., Wang, Y., & McDonald, S. D. (2021). Untreated depression during pregnancy and its effect on pregnancy outcomes: A systematic review. Cureus, 13(8), e17251. https://doi.org/10.7759/cureus.17251
McDonagh, M. S., Matthews, A., Phillipi, C., Romm, J., Peterson, K., Thakurta, S., & Guise, J. M. (2014). Depression drug treatment outcomes in pregnancy and the postpartum period: A systematic review and meta-analysis. Obstetrics & Gynecology, 124(3), 526–534. https://doi.org/10.1097/AOG.0000000000000410
Neonatal adaptation in infants prenatally exposed to antidepressants: Clinical monitoring using Neonatal Abstinence Score. (2014). PLOS ONE, 9(11), e111327. https://doi.org/10.1371/journal.pone.0111327
Nörby, U., Winbladh, B., Källén, K., & Källén, B. (2016). Neonatal morbidity after maternal use of antidepressant drugs during pregnancy. Pediatrics, 138(5), e20160181. https://doi.org/10.1542/peds.2016-0181
Palmsten, K., Huybrechts, K. F., Kowal, M. K., Mogun, H., Hernández-Díaz, S., & Wisner, K. L. (2020). Maternal and fetal outcomes following exposure to duloxetine in pregnancy: Cohort study. BMJ, 368, m237. https://doi.org/10.1136/bmj.m237
Ross, L. E., Grigoriadis, S., Mamisashvili, L., VonderPorten, E. H., Roerecke, M., Rehm, J., Dennis, C.-L., Koren, G., Steiner, M., Mousmanis, P., & Cheung, A. (2013). Selected pregnancy and delivery outcomes after exposure to antidepressant medication: A systematic review and meta-analysis. JAMA Psychiatry, 70(4), 436–443. https://doi.org/10.1001/jamapsychiatry.2013.684
Ross, L. E., Grigoriadis, S., Mamisashvili, L., VonderPorten, E. H., Roerecke, M., Rehm, J., Dennis, C.-L., Koren, G., Steiner, M., Mousmanis, P., & Cheung, A. (2016). Antidepressant use in pregnancy: A critical review focused on methodological issues. Acta Psychiatrica Scandinavica, 134(6), 493–506. https://doi.org/10.1111/acps.12672
Selective serotonin reuptake inhibitors (SSRIs) in pregnancy. (2022). Therapeutic Advances in Drug Safety, 13, 1–15. https://pmc.ncbi.nlm.nih.gov/articles/PMC10590209/
Yin, X., Sun, N., Jiang, N., Xu, X., Gan, Y., Zhang, J., Qiu, L., Yang, C., Shi, X., Chang, J., & Gong, Y. (2016). Neonatal outcomes in women with untreated antenatal depression: A meta-analysis. JAMA Psychiatry, 73(8), 826–837. https://doi.org/10.1001/jamapsychiatry.2016.0934
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Anna Kiełboń, Maja Osuch, Maciej Osuch, Olga Tatarata, Martyna Jaciubek, Carmena Luty, Amanda Abramowicz, Magdalena Rumin, Zuzanna Olga Reklewska, Kornelia Domagała
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
